DPYD genotype-guided dose personalisation for fluoropyrimidine-based chemotherapy prescribing in solid organ cancer patients in Australia: GeneScreen 5-FU study protocol.

Saved in:
Bibliographic Details
Title: DPYD genotype-guided dose personalisation for fluoropyrimidine-based chemotherapy prescribing in solid organ cancer patients in Australia: GeneScreen 5-FU study protocol.
Authors: White C; University of Newcastle, College of Health, Medicine and Wellbeing, School of Medicine and Public Health, Callaghan, NSW, 2308, Australia. cassandra.white10@uon.edu.au.; Hunter Medical Research Institute, Lot 1, Kookaburra Circuit, New Lambton Heights, NSW, 2305, Australia. cassandra.white10@uon.edu.au., Wardill H; School of Biomedicine, University of Adelaide, Adelaide, SA, 5005, Australia.; Supportive Oncology Research Group, Precision Cancer Medicine, South Australian Health and Medical Research Institute, Adelaide, SA, 5000, Australia., Paul C; University of Newcastle, College of Health, Medicine and Wellbeing, School of Medicine and Public Health, Callaghan, NSW, 2308, Australia.; Hunter Medical Research Institute, Lot 1, Kookaburra Circuit, New Lambton Heights, NSW, 2305, Australia., Price T; The Queen Elizabeth Hospital and University of Adelaide, Adelaide, SA, 5005, Australia., Karapetis C; Flinders University and Flinders Medical Centre, Bedford Park, SA, 5042, Australia., Nalder M; Royal Brisbane and Women's Hospital, Brisbane, QLD, 4006, Australia.; University of Queensland, Brisbane, QLD, 4006, Australia., Burge ME; Royal Brisbane and Women's Hospital, Brisbane, QLD, 4006, Australia., Thomas A; Hunter Medical Research Institute, Lot 1, Kookaburra Circuit, New Lambton Heights, NSW, 2305, Australia., Oldmeadow C; Hunter Medical Research Institute, Lot 1, Kookaburra Circuit, New Lambton Heights, NSW, 2305, Australia., Barker D; Hunter Medical Research Institute, Lot 1, Kookaburra Circuit, New Lambton Heights, NSW, 2305, Australia., Edney LC; Flinders University, College of Medicine and Public Health; Flinders Health and Medical Research Institute, Adelaide, SA, 5042, Australia., Coller J; School of Biomedicine, University of Adelaide, Adelaide, SA, 5005, Australia., Bowen J; School of Biomedicine, University of Adelaide, Adelaide, SA, 5005, Australia., Ostroff C; University of South Australia, Centre for Workplace Excellence, Adelaide, SA, 5001, Australia., Cheek B; Australasian Gastrointestinal Trials Group (Consumer Panel), Camperdown, NSW, 2050, Australia.; Cancer Quality of Life Expert Service Team (Member Steering Committee), University of Technology Sydney, Ultimo, NSW, 2007, Australia.; Cancer Voices New South Wales (Consumer Representative), Milsons Point, NSW, 1565 , Australia., Carlson M; University of Newcastle, College of Health, Medicine and Wellbeing, School of Medicine and Public Health, Callaghan, NSW, 2308, Australia.; Hunter Medical Research Institute, Lot 1, Kookaburra Circuit, New Lambton Heights, NSW, 2305, Australia., Rankmore T; Hunter Medical Research Institute, Lot 1, Kookaburra Circuit, New Lambton Heights, NSW, 2305, Australia., Nagrial A; Western Sydney Local Health District, Westmead, NSW, 2148, Australia.; University of Sydney, Westmead Clinical School, Westmead, NSW, 2148, Australia., Clarke S; Northern Sydney Local Health District, St. Leonards, NSW, 2065, Australia.; University of Sydney, Northern Clinical School, St. Leonards, NSW, 2065, Australia., Chantrill L; Illawarra Shoalhaven Local Health District, Wollongong, NSW, 2500, Australia.; University of Wollongong, Wollongong, NSW, 2500, Australia., Ackland S; University of Newcastle, College of Health, Medicine and Wellbeing, School of Medicine and Public Health, Callaghan, NSW, 2308, Australia.; Hunter Medical Research Institute, Lot 1, Kookaburra Circuit, New Lambton Heights, NSW, 2305, Australia., Scott RJ; University of Newcastle, College of Health, Medicine and Wellbeing, School of Biomedical Science and Pharmacy, Callaghan, NSW, 2308, Australia.; Department of Molecular Genetics, Pathology North John Hunter Hospital, New Lambton Heights, NSW, 2305, Australia.
Source: BMC cancer [BMC Cancer] 2024 Nov 08; Vol. 24 (1), pp. 1369. Date of Electronic Publication: 2024 Nov 08.
Publication Type: Journal Article; Clinical Trial Protocol
Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1471-2407
DOI:10.1186/s12885-024-13122-8